Denosumab biosimilar press release detailing a company's development program, strategic commercialization plans, and what it could mean for patients and industry.
Key Takeaways
- Phase III trial met pre-specified equivalence on lumbar spine BMD change
- Japan marketing authorization submission is expected in the third quarter of 2026
- Company plans dual indications and completed comparative quality package for both originator indications